Alpha Teknova, Inc. (TKNO) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Alpha Teknova, Inc. is a Delaware corporation and an emerging growth company that manufactures critical reagents for the life sciences market, including cell culture media, supplements, and molecular biology reagents. The company operates a single manufacturing facility in Hollister, California.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Revenue | $9,576 | $8,169 | $28,480 | $28,817 |
| Gross Profit | $90 | $1,472 | $5,103 | $8,961 |
| Gross Margin | 0.9% | 18.0% | 17.9% | 31.1% |
| Operating Loss | $(7,432) | $(8,762) | $(20,518) | $(24,705) |
| Net Loss | $(7,565) | $(10,153) | $(21,026) | $(26,124) |
| Cash & Short-term Investments | $31,691 | N/A | N/A | N/A |
| Long-term Debt (Net) | $10,857 | N/A | N/A | N/A |
Note: Cash and short-term investments combined total $31.691 million as of September 30, 2024 ($6.145M cash + $25.546M short-term investments).
Material Changes vs. Prior Period
- Revenue Growth (Q3): Revenue increased 17.2% year-over-year to $9.6 million, driven primarily by a 229% surge in Clinical Solutions revenue ($2.0M vs $0.6M). Lab Essentials revenue remained relatively flat.
- Gross Margin Compression: Gross margin collapsed to 0.9% in Q3 2024 from 18.0% in Q3 2023. Management attributes this to a $2.8 million non-recurring, non-cash charge for the disposal of expired inventory and write-down of excess inventory created in late 2022. Excluding this charge, the adjusted gross margin would have been 29.8%.
- Operating Expense Reduction: Total operating expenses decreased 26.5% year-over-year to $7.5 million, driven by workforce reductions implemented in early 2024 and reduced spending on professional fees and insurance.
- Capital Raise: In July 2024, the company completed a private placement raising approximately $15.4 million in gross proceeds, significantly bolstering liquidity.
Outlook, Risks, and Management Commentary
- Going Concern Status: Management states there is no longer substantial doubt about the company's ability to continue as a going concern for the next 12 months, citing recent capital raises, cost reductions, and compliance with amended credit covenants.
- Debt Covenants: The company amended its credit agreement (Amendment No. 5) in March 2024, reducing minimum net revenue requirements for periods through December 2024 from $42.0 million to $34.0 million. The company was in compliance as of September 30, 2024.
- Workforce Reductions: The company reduced its workforce by approximately 35 positions in January 2024, incurring $1.3 million in costs. Risks include potential impacts on morale and the ability to meet customer demand.
- Legal Contingencies: A former employee filed a wage and hour claim. The company accrued $0.4 million for a settlement agreement reached in June 2024, pending court approval.
- Stock Option Repricing: In January 2024, the board approved a repricing of certain stock options to $2.97 per share, effective September 2025, resulting in incremental stock-based compensation expense.
Investor Verification Checklist
- Inventory Valuation: Verify the nature and extent of the $2.8 million inventory write-down and assess if future write-downs are likely given the company's production history.
- Covenant Compliance: Monitor the company's ability to meet the revised minimum net revenue covenant of $34.0 million for the trailing twelve months ending December 31, 2024.
- Liquidity Runway: Assess the burn rate against the current cash position of ~$31.7 million to determine the runway without further dilution or debt financing.
- Customer Concentration: Review the reliance on "Distributor customer A," which accounted for 19% of Q3 2024 revenue.
- Settlement Finalization: Confirm the finalization of the $0.4 million legal settlement with the former employee.